Historical Valuation
Nuvation Bio Inc (NUVB) is now in the Fair zone, suggesting that its current forward PS ratio of 19.10 is considered Fairly compared with the five-year average of -8.68. The fair price of Nuvation Bio Inc (NUVB) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：8.04
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Nuvation Bio Inc (NUVB) has a current Price-to-Book (P/B) ratio of 9.02. Compared to its 3-year average P/B ratio of 1.80 , the current P/B ratio is approximately 400.62% higher. Relative to its 5-year average P/B ratio of 2.67, the current P/B ratio is about 237.38% higher. Nuvation Bio Inc (NUVB) has a Forward Free Cash Flow (FCF) yield of approximately -6.47%. Compared to its 3-year average FCF yield of -17.00%, the current FCF yield is approximately -61.96% lower. Relative to its 5-year average FCF yield of -13.62% , the current FCF yield is about -52.53% lower.
P/B
Median3y
1.80
Median5y
2.67
FCF Yield
Median3y
-17.00
Median5y
-13.62
Competitors Valuation Multiple
AI Analysis for NUVB
The average P/S ratio for NUVB competitors is 47.68, providing a benchmark for relative valuation. Nuvation Bio Inc Corp (NUVB.N) exhibits a P/S ratio of 19.10, which is -59.94% above the industry average. Given its robust revenue growth of 1704.68%, this premium appears sustainable.
Performance Decomposition
AI Analysis for NUVB
1Y
3Y
5Y
Market capitalization of NUVB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NUVB in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is NUVB currently overvalued or undervalued?
Nuvation Bio Inc (NUVB) is now in the Fair zone, suggesting that its current forward PS ratio of 19.10 is considered Fairly compared with the five-year average of -8.68. The fair price of Nuvation Bio Inc (NUVB) is between to according to relative valuation methord.
What is Nuvation Bio Inc (NUVB) fair value?
NUVB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Nuvation Bio Inc (NUVB) is between to according to relative valuation methord.
How does NUVB's valuation metrics compare to the industry average?
The average P/S ratio for NUVB's competitors is 47.68, providing a benchmark for relative valuation. Nuvation Bio Inc Corp (NUVB) exhibits a P/S ratio of 19.10, which is -59.94% above the industry average. Given its robust revenue growth of 1704.68%, this premium appears sustainable.
What is the current P/B ratio for Nuvation Bio Inc (NUVB) as of Jan 11 2026?
As of Jan 11 2026, Nuvation Bio Inc (NUVB) has a P/B ratio of 9.02. This indicates that the market values NUVB at 9.02 times its book value.
What is the current FCF Yield for Nuvation Bio Inc (NUVB) as of Jan 11 2026?
As of Jan 11 2026, Nuvation Bio Inc (NUVB) has a FCF Yield of -6.47%. This means that for every dollar of Nuvation Bio Inc’s market capitalization, the company generates -6.47 cents in free cash flow.
What is the current Forward P/E ratio for Nuvation Bio Inc (NUVB) as of Jan 11 2026?
As of Jan 11 2026, Nuvation Bio Inc (NUVB) has a Forward P/E ratio of -15.02. This means the market is willing to pay $-15.02 for every dollar of Nuvation Bio Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Nuvation Bio Inc (NUVB) as of Jan 11 2026?
As of Jan 11 2026, Nuvation Bio Inc (NUVB) has a Forward P/S ratio of 19.10. This means the market is valuing NUVB at $19.10 for every dollar of expected revenue over the next 12 months.